Government-Owned Inventions; Availability for Licensing, 46490-46491 [06-6879]
Download as PDF
<![CDATA[
46490
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
taper ensures higher damage threshold
for the delivery waveguide in
comparison to the conventional lens
laser-to-fiber coupling. To improve the
high-peak-power delivery capability of
the proposed allow-hollow-waveguide
DPIV illumination system, instead of a
conventional solid-core fiber link, we
have used a cyclic olefin polymer
(COP)-coated hollow glass waveguide
which is designed to minimize the
waveguide attenuation losses at a
typical DPIV laser wavelength of 532nm. This waveguide provides a
significantly higher laser power delivery
capability and higher damage threshold.
The all-hollow-waveguide DPIV laser
delivery system offers essential
advanced features over conventional
bulk-optics-based delivery techniques in
terms of formatting thin (0.5–1.0 mm),
wide (10 mm or wider) and uniform
laser illumination sheet; high-peakpower laser delivery without damaging
effects (> 1 GW/cm2), flexibility,
miniaturization, simplified alignment,
immunity to external influence
(including vibrations and angular laser
beam drift), and safe and confined laser
delivery.
Applications
2. Optics; Particle imaging:
Velocimetry.
jlentini on PROD1PC65 with NOTICES
Collaborative Research Opportunity
The Food and Drug Administration’s
Center for Devices and Radiological
Health is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact the inventors at 301/827–4685
for more information.
Dated: July 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer; Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6873 Filed 8–11–06; 8:45 am]
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
Publications
1. IK Ilev et al., ‘‘Grazing-IncidenceBased Hollow Taper for Infrared Laserto-Fiber Coupling,’’ Applied Physics
Letters, Vol. 74, 1999, pp. 2921–2923.
2. IK Ilev et al., ‘‘Uncoated Hollow
Taper as a Single Optical Funnel for
Laser Delivery,’’ Review of Scientific
Instruments, Vol. 70, 1999, pp. 3840–
3843.
3. IK Ilev et al., ‘‘Ultraviolet Laser
Delivery Using an Uncoated Hollow
Taper,’’ IEEE Journal of Quantum
Electronics, Vol. 36, 2000, pp. 944–948.
4. IK Ilev et al., ‘‘Attenuation
Measurement of Infrared Optical Fibers
Using a Hollow-Taper-Based Coupling
Method,’’ Applied Optics, Vol. 39, 2000,
pp. 3192–3196.
5. RA Robinson et al., ‘‘Design and
Optimization of a Flexible High-Peak
Power Laser-to-Fiber Coupled
Illumination System Used in Digital
Particle Image Velocimetry’’, Review of
Scientific Instruments, Vol. 75, 2004,
pp. 4856–4862.
Jkt 208001
Licensing Contact
Michael A. Shmilovich, Esq.; 301/
435–5019. shmilovm.@mail.nih.gov.
<mailto:shmilovm@mail.nih.gov.>
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Inventors
6. Ilko K. Ilev, Ronald A. Robinson,
Ronald W. Waynant (FDA).
17:58 Aug 11, 2006
Licensing Status
10. Available for non-exclusive or
exclusive licensing.
BILLING CODE 4140–01–M
Market
4. Illumination, high peak laser
powered delivery.
VerDate Aug<31>2005
Patent Status
8. U.S. Provisional Application No.
60/730,866 filed 28 Oct 2005 (HHS
Reference No. AE–015–2006/0–US–01).
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Model Th1 Clone Producing IFNgamma and IL–2
Description of Technology
Available for licensing is the A.E7 T
cell clone, a model Th1 clone described
in Matis et al., J Immunol. 1983 Apr
130(4):1527–1535 [PubMed abs] and J
Immunol. 1983 Sept 131(3):1049–1055
[PubMed abs]. This clone has been
further utilized as a model for studying
T cell clonal anergy.
Potential Applications of Technology
2. Model Th1 clone capable of making
IFN-gamma and IL–2
4. Model T cell clone for studying T
cell clonal anergy
Inventors
Ronald H. Schwartz et al. (NIAID).
Louis A. Matis (NIAID).
Dan L. Longo (NCI).
Toby T. Hecht (NCI).
Patent Status
HHS Reference No. E–214–2006/0—
Research Tool.
Licensing Status
Available for non-exclusive licensing.
Licensing Contact
Susan Ano, Ph.D.; Phone: (301) 435–
5515; Email: anos@mail.nih.gov.
Dated: July 31, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6874 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditions
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
E:\FR\FM\14AUN1.SGM
14AUN1
Federal Register / Vol. 71, No. 156 / Monday, August 14, 2006 / Notices
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; telephone: 301/496–0220.
A signed Confidential Disclosure
Agreement will be required to receive
copies of the patent applications.
Complement Regulatory Gene Variants
as Predictive Tests for Age-related
Macular Degeneration (AMD)
jlentini on PROD1PC65 with NOTICES
Description of Technology
Age-related macular degeneration
(AMD) is complex multigenic disorder
that affects the central region of the
retina (macula) and is the leading cause
of legal blindness in developed
countries. Age, lifestyle (e.g., smoking,
diet) and genetic predisposition are
major risk factors for AMD and 1.75
million adults over 40 are affected by
advanced AMD in the United States
with a further 7 million considered to be
at risk (defined by the presence of large
retinal deposits or drusen, which are the
hallmark of this disease). A variety of
immune-associated molecules including
immunoglobulins, complement
components, activators and regulators,
etc. are associated with drusen and
evidence suggests that AMD, like other
age-related diseases such as Alzheimer’s
disease and atherosclerosis, involves a
major inflammatory component. Several
disease-susceptibility genes have been
identified in family studies of macular
degeneration and in patient cohorts by
several groups including NIH
researchers and their collaborators, and
variants in the factor H gene (CFH)), a
major inhibitor of the alternative
complement pathway, have been
associated with the risk for developing
AMD.
NIH researchers and their
collaborators have now extended this
work to two other regulatory genes of
this pathway, Factor B (BF) and
complement component 2 (C2). These
genes were screened for genetic
variation in two independent cohorts
comprised of ~900 AMD cases and
~400 matched controls. Haplotype
analyses revealed a significant common
risk haplotype (H1) and two protective
haplotypes (H7 and H10). Combined
analysis of the C2/BF haplotypes and
CFH variants shows that variation in the
two loci can predict the clinical
outcome in 74% of the cases and 56%
of the controls (Nature Genetics (2006)
38, 458). This suggests that these
variants can be used as predictive
genetic tests in combination with other
potential risk factors.
VerDate Aug<31>2005
17:58 Aug 11, 2006
Jkt 208001
Available for licensing are methods
for identifying a subject at increased risk
for developing AMD by determining the
presence of protective genotypes at
either the BF/C2 locus and at the CFH
locus. Microarrays and kits are also
provided. The complex and polygenic
nature of AMD suggests that the
protective and risk haplotypes claimed
here can be of great value not only to
companies targeting Macular
Degeneration but perhaps more broadly
to those involved in complementmediated inflammatory disorders.
Inventors
Michael Dean (NCI), Bert Gold (NCI)
et al.
Patent Status
U.S. Provisional Patent Application
No. 60/772,989, filed 13 February 2006
(HHS Reference No. E–042–2006/0–US–
01).
Licensing Status
Available for non-exclusive or
exclusive licensing.
Licensing Contract
Susan Carson, D.Phil.; 301–435–5020;
mail to: carsonsu@mail.nih.gov.
Collaborative Research Opportunity
The NCI Laboratory of Genomic
Diversity is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize functional or genetic
tests on complement genes and proteins.
Please contact Kathleen Higinbotham at
301–846–5465 for more information.
Dated: July 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 06–6879 Filed 8–11–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
46491
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Licensing Opportunity
From the National Institutes of Health
Target-Specific Activatable Optical
Probes for In Vivo Imaging
Description of Technology
Available for licensing and
commercial development is an optical
imaging method capable of detecting
living cancer cells in vivo. The method
increases sensitivity and reduces the
background signal to extremely low
levels. In contrast to conventional
fluorescent imaging, the strategy
activates the probe after it binds to and
is internalized within cancer cells.
Using antibodies, reagent-receptor
systems, or cytokines to target the agent
to the cancer, the agent is internalized
by the normal cellular process of
endocytosis which in turn, leads to
molecular changes within the probe
itself; fluorophores are activated only in
the living targeted cells.
An activatable fluorophore is one that
is normally self-quenched by
attachment to a peptide backbone but
which can be activated by specific
proteases which degrade the peptide
resulting in ‘‘de-quenching.’’ For
example, self-quenching avidinrhodaminex, which has affinity for
lectin on cancer cells, is activated after
endocytosis and degradation within the
lysosome. Cellular internalization of
receptor-ligand pairs with subsequent
activation of fluorescence via ‘‘dequenching’’ provides a generalizable
and highly sensitive method of
detecting cancer microfoci in vivo and
has practical implications for assisting
surgical and endoscopic procedures.
Application(s)
2. Optical detection of tumor cells and
metastatic nodules
4. Photodynamic treatment of tumors
E:\FR\FM\14AUN1.SGM
14AUN1
]]>Agencies
[Federal Register Volume 71, Number 156 (Monday, August 14, 2006)]
[Notices]
[Pages 46490-46491]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditions commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications
[[Page 46491]]
listed below may be obtained by writing to the indicated licensing
contact at the Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
telephone: 301/496-0220. A signed Confidential Disclosure Agreement
will be required to receive copies of the patent applications.
Complement Regulatory Gene Variants as Predictive Tests for Age-related
Macular Degeneration (AMD)
Description of Technology
Age-related macular degeneration (AMD) is complex multigenic
disorder that affects the central region of the retina (macula) and is
the leading cause of legal blindness in developed countries. Age,
lifestyle (e.g., smoking, diet) and genetic predisposition are major
risk factors for AMD and 1.75 million adults over 40 are affected by
advanced AMD in the United States with a further 7 million considered
to be at risk (defined by the presence of large retinal deposits or
drusen, which are the hallmark of this disease). A variety of immune-
associated molecules including immunoglobulins, complement components,
activators and regulators, etc. are associated with drusen and evidence
suggests that AMD, like other age-related diseases such as Alzheimer's
disease and atherosclerosis, involves a major inflammatory component.
Several disease-susceptibility genes have been identified in family
studies of macular degeneration and in patient cohorts by several
groups including NIH researchers and their collaborators, and variants
in the factor H gene (CFH)), a major inhibitor of the alternative
complement pathway, have been associated with the risk for developing
AMD.
NIH researchers and their collaborators have now extended this work
to two other regulatory genes of this pathway, Factor B (BF) and
complement component 2 (C2). These genes were screened for genetic
variation in two independent cohorts comprised of ~900 AMD cases and
~400 matched controls. Haplotype analyses revealed a significant common
risk haplotype (H1) and two protective haplotypes (H7 and H10).
Combined analysis of the C2/BF haplotypes and CFH variants shows that
variation in the two loci can predict the clinical outcome in 74% of
the cases and 56% of the controls (Nature Genetics (2006) 38, 458).
This suggests that these variants can be used as predictive genetic
tests in combination with other potential risk factors.
Available for licensing are methods for identifying a subject at
increased risk for developing AMD by determining the presence of
protective genotypes at either the BF/C2 locus and at the CFH locus.
Microarrays and kits are also provided. The complex and polygenic
nature of AMD suggests that the protective and risk haplotypes claimed
here can be of great value not only to companies targeting Macular
Degeneration but perhaps more broadly to those involved in complement-
mediated inflammatory disorders.
Inventors
Michael Dean (NCI), Bert Gold (NCI) et al.
Patent Status
U.S. Provisional Patent Application No. 60/772,989, filed 13
February 2006 (HHS Reference No. E-042-2006/0-US-01).
Licensing Status
Available for non-exclusive or exclusive licensing.
Licensing Contract
Susan Carson, D.Phil.; 301-435-5020; mail to:
carsonsu@mail.nih.gov.
Collaborative Research Opportunity
The NCI Laboratory of Genomic Diversity is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize functional or
genetic tests on complement genes and proteins. Please contact Kathleen
Higinbotham at 301-846-5465 for more information.
Dated: July 28, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 06-6879 Filed 8-11-06; 8:45 am]
BILLING CODE 4140-01-M
